ruthenium Dotaz Zobrazit nápovědu
FN v Motole zahájila léčbu pacientů trpících retinoblastomem brachyterapií po udělení oprávnění k nakládání s uzavřeným zdrojem ionizujícího záření na počátku roku 2003. Zvolili jsme aplikátor obsahující I06Ru emitující převážně beta záření o maximální energii 3,5 MeV s malou příměsí gama záření o energii 512, 622 keV a 2% s energií lMeV. Poločas rozpadu činí 369 dní a nominální aktivita zdroje 21,1 MBq. Zdroj aplikujeme najeden až několik dní v závislosti na prominenci tumoru a aktuální aktivitě zdroje. Doba aplikace se vypočítává podle speciálního programu. V roce 2003 jsme brachyterapií léčili tři pacienty trpící retinoblastomem. V jednom případě se jednalo o bilaterální onemocnění a brachyterapie byla využita pro léčbu obou očí. Další pacient byl léčen dvakrát po sobě s různou lokalizací aplikátoru, vzhledem k značnému plošnému rozsahu nádoru. Celkem jsme tedy brachyterapií pro léčbu retinoblastomu v roce 2003 použili pětkrát. Ve všech případech se jednalo o kombinovanou léčbu (chemoredukce, teleterapie, transpupilární termoterapie nebo kryotera-pie). Jeden bulbus byl enukleován pro těžkou poradiační retinopatii, druhý pro pokračující trakční odchlípení sítnice. V ostatních případech jsme neshledali závažné komplikace ani progresi nádorového onemocnění.
The Charles University Teaching Hospital in Prague - Motol started to treat patients with retinoblastoma by means of brachytherapy after obtaining the permission to use closed source of ionizing radiation in the beginning of the year 2003. The applicator containing ruthenium (106Ru) emitting mostly the beta radiation was chosen. Half-life is 369 days and the nominal activity of the source is 21.1 MBq. The applicator is placed in pláce for one to several days according to the prominence of the tumor and actual activity of the source. Duration of the application is calculated with a speciál program. In the year 2003, three patients with retinoblastoma were treated. In one čase bilateral involvement was determined, and the brachytherapy was ušed for treatment of both eyes. The next patient was treated twice; one treatment followed the other with different localization of the applicator because of too large basis of the tumor. In 2003, altogether the brachytherapy was ušed for treatment of retinoblastoma fivc times. In all cascs, the combined treatment (chemo reduction, teletherapy, transpupillary thermotherapy, or cryotherapy) was performed. One eyeball was enucleated because of severe post-radiation retinopathy, the second one for persisting tractional retinal detachment. In remaining cases no serious complications or progression of the malignancy were observed.
- MeSH
- brachyterapie metody přístrojové vybavení MeSH
- dítě MeSH
- finanční podpora výzkumu jako téma MeSH
- ionizující záření MeSH
- kojenec MeSH
- lidé MeSH
- radioizotopy ruthenia aplikace a dávkování terapeutické užití MeSH
- retinoblastom diagnóza radioterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- Publikační typ
- přehledy MeSH
This study was a comparison between Ru-catalysts and similar, previously investigated, Pt-catalysts. In this paper, ruthenium catalysts for catalytic wet air oxidation are prepared, characterized and tested. Both catalysts were supported on commercial CeO2 as well as mixed oxide Zr(0.1)(Ce(0.75)Pr(0.25))(0.9)O2. The catalysts were characterized by measuring the oxygen storage capacities (OSC), BET, XRD, FTIR and chemisorption of hydrogen. In addition, the effect of sintering (treatments under H2) was compared with both of the catalysts. The comparison of the results showed that initial intrinsic activity of ruthenium is not significantly influenced by the type of the support, which is contrast to platinum. Furthermore, the particle size of Ru had an important effect on CWAO activity: the higher the particle size, the better the activity. This was different with Pt-catalysts, where the optimal particle size was smaller, having about 15% of metal dispersion.
- MeSH
- cer MeSH
- katalýza MeSH
- kyselina octová chemie MeSH
- oxidace-redukce MeSH
- oxidy MeSH
- platina MeSH
- ruthenium MeSH
- velikost částic MeSH
- vzduch MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
Metastatic cancer remains a formidable challenge in anticancer therapy. Despite efforts to develop effective antimetastasis drugs over the past half-century, currently approved treatments fall short of expectations. This report highlights the promising antiproliferative activity of a ruthenium-based therapeutic agent, namely dichlorido(p-cymene)[2-amino-4-(pyridin-3-yl)-4H-benzo[h]-chromene-3-carbonitrile]ruthenium(II) (complex 1) against metastatic cell lines. Complex 1 shows significant efficacy in metastatic LoVo and Du-145 cell lines at nanomolar concentrations, being markedly more active than clinically used anticancer cisplatin. Studies on the MDA-MB-231 cell line, which displays invasive characteristics, demonstrated that 1 significantly reduces cell invasion. This efficacy was confirmed by its impact on matrix metalloproteinase production in MDA-MB-231 cells. Given that cell migration drives cancer invasion and metastasis, complex 1's effect on MDA-MB-231 cell migration was evaluated via wound healing assay and vimentin network analysis. Results indicated a strong reduction in migration. A re-adhesion assay further demonstrated that 1 significantly lowers the re-adhesion ability of MDA-MB-231 cells compared to cisplatin. To better simulate the human body environment, a 3D spheroid invasion assay was used. This method showed that 1 effectively inhibits tumor spheroids from infiltrating the surrounding extracellular matrix. This study underscores the potential of (arene)ruthenium(II) complexes with naphthopyran ligands as potent antimetastatic agents for chemotherapy.
- MeSH
- buněčná adheze účinky léků MeSH
- komplexní sloučeniny * farmakologie chemie terapeutické užití MeSH
- lidé MeSH
- metastázy nádorů prevence a kontrola farmakoterapie MeSH
- nádorové buněčné linie MeSH
- pohyb buněk * účinky léků MeSH
- proliferace buněk účinky léků MeSH
- protinádorové látky * farmakologie chemie terapeutické užití MeSH
- ruthenium * chemie farmakologie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The current epidemic of antibiotic-resistant infections urges to develop alternatives to less-effective antibiotics. To assess anti-bacterial potential, a novel coordinate compound (RU-S4) was synthesized using ruthenium-Schiff base-benzimidazole ligand, where ruthenium chloride was used as the central atom. RU-S4 was characterized by scanning electron microscope (SEM), energy-dispersive X-ray spectroscopy (EDS), and Raman spectroscopy. Antibacterial effect of RU-S4 was studied against Staphylococcus aureus (NCTC 8511), vancomycin-resistant Staphylococcus aureus (VRSA) (CCM 1767), methicillin-resistant Staphylococcus aureus (MRSA) (ST239: SCCmecIIIA), and hospital isolate Staphylococcus epidermidis. The antibacterial activity of RU-S4 was checked by growth curve analysis and the outcome was supported by optical microscopy imaging and fluorescence LIVE/DEAD cell imaging. In vivo (balb/c mice) infection model prepared with VRSA (CCM 1767) and treated with RU-S4. In our experimental conditions, all infected mice were cured. The interaction of coordination compound with bacterial cells were further confirmed by cryo-scanning electron microscope (Cryo-SEM). RU-S4 was completely non-toxic against mammalian cells and in mice and subsequently treated with synthesized RU-S4.
- MeSH
- antibakteriální látky chemie farmakologie MeSH
- Bacteria účinky léků MeSH
- buněčné linie MeSH
- komplexní sloučeniny chemie farmakologie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- molekulární struktura MeSH
- myši MeSH
- Ramanova spektroskopie MeSH
- ruthenium chemie MeSH
- viabilita buněk účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
While ruthenium arene complexes have been widely investigated for their medicinal potential, studies on homologous compounds containing a tridentate tris(1-pyrazolyl)methane ligand are almost absent in the literature. Ruthenium(II) complex 1 was obtained by a modified reported procedure; then, the reactions with a series of organic molecules (L) in boiling alcohol afforded novel complexes 2-9 in 77-99% yields. Products 2-9 were fully structurally characterized. They are appreciably soluble in water, where they undergo partial chloride/water exchange. The antiproliferative activity was determined using a panel of human cancer cell lines and a noncancerous one, evidencing promising potency of 1, 7, and 8 and significant selectivity toward cancer cells. The tested compounds effectively accumulate in cancer cells, and mitochondria represent a significant target of biological action. Most notably, data provide convincing evidence that the mechanism of biological action is mediated by the inhibiting of mitochondrial calcium intake.
- MeSH
- homeostáza MeSH
- komplexní sloučeniny * farmakologie MeSH
- lidé MeSH
- mitochondrie MeSH
- nádorové buněčné linie MeSH
- nádory * farmakoterapie MeSH
- protinádorové látky * farmakologie terapeutické užití MeSH
- ruthenium * farmakologie MeSH
- vápník MeSH
- voda MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
